Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
Wysham CH, Rosenstock J, Vetter ML, Wang H, Hardy E, Iqbal N. Wysham CH, et al. Among authors: iqbal n. BMJ Open Diabetes Res Care. 2020 Oct;8(1):e000773. doi: 10.1136/bmjdrc-2019-000773. BMJ Open Diabetes Res Care. 2020. PMID: 33037036 Free PMC article. Clinical Trial.
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P; DURATION-NEO-2 study investigators. Gadde KM, et al. Among authors: iqbal n. Diabetes Obes Metab. 2017 Jul;19(7):979-988. doi: 10.1111/dom.12908. Epub 2017 Mar 17. Diabetes Obes Metab. 2017. PMID: 28205322 Free PMC article. Clinical Trial.
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C. Del Prato S, et al. Among authors: iqbal n. Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25. Diabetes Obes Metab. 2018. PMID: 29446523 Free PMC article. Clinical Trial.
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J. Handelsman Y, et al. Among authors: iqbal n. Diabetes Obes Metab. 2019 Apr;21(4):883-892. doi: 10.1111/dom.13594. Epub 2019 Jan 3. Diabetes Obes Metab. 2019. PMID: 30499237 Free PMC article. Clinical Trial.
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Rosenstock J, et al. Among authors: iqbal n. Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28. Diabetes Care. 2015. PMID: 25352655 Clinical Trial.
1,124 results